• New Strategy to Predict Early Sepsis

  NCT04118179

  Unknown statusObservationalUpdated Jun 5, 2023
• Near Patient Molecular Testing in Sepsis

  NCT05469048

  CompletedObservationalUpdated Oct 2, 2024
• Sepsis Pre-Alert Monitoring Intervention: Study to Investigate Targeted Enhanced Monitoring for Sepsis

  NCT03473769

  WithdrawnInterventionalNot ApplicableUpdated Oct 9, 2024
• Molecular Biomarkers for Sepsis

  NCT04280354

  TerminatedObservationalUpdated May 9, 2024
• Early Diagnosis and Prognosis of Postoperative Sepsis by Presepsin and Syndecan-1

  NCT04718623

  Unknown statusObservationalUpdated Jan 22, 2021
• Improved Detection of Neonatal Sepsis Using a Targeted Biomarker Assay

  NCT01120678

  CompletedObservationalUpdated Nov 4, 2020

ClinicalTrials.gov ID

NCT04189549

Lead Sponsor

Robert EhrmanOTHER

Overall Status

Unknown status

Study Type

Observational

Enrollment

2,000Estimated

Last Update Posted

Dec 6, 2019Actual

Start Date

Dec 9, 2019Estimated

Primary Completion Date

Nov 1, 2020Estimated

Completion Date

Apr 30, 2021Estimated

Official Title

Preclinical Detection of Sepsis Early in Hospitalized Patients Following Surgery, Injury or Severe Illness (Pre-SEPSIS Trial)

Brief Summary

This clinical study is to evaluate a novel biomarker - CNA Rapid Sepsis Dx - to predict the development of sepsis in patients admitted to the hospital with non-sepsis conditions. Using circulating cell-free DNA (cfDNA) in the blood stream, it has been demonstrated to detect infection response days before clinical evidence of sepsis manifests. The hypothesis is that blood biomarkers drawn daily in the hospital will identify patients who develop sepsis within seven days of hospital presentation.

Detailed Description

This is a prospective observational trial evaluating CNA Rapid Sepsis Dx -novel biomarkers (CNA Diagnostics Inc.; Calgary, Canada) based on circulating cell-free DNA (cfDNA) in the blood stream to identify patients originally admitted with non-sepsis conditions who ultimately develop sepsis according to Sepsis-3 criteria within seven days of hospital presentation. This novel technology has been demonstrated to detect host-related response to infection days before clinical evidence of sepsis manifests.

The primary objective of this study is to assess the performance of the novel diagnostic assay, CNA Rapid Sepsis Dx, based on the biomarkers, drawn daily from the day of hospital presentation, to identify patients who ultimately develop sepsis according to Sepsis-3-definition within seven days of hospital presentation.

The secondary objective is to correlate the CNA Rapid Sepsis Dx with clinically relevant outcomes such as infections that otherwise do not meet Sepsis-3 criteria, intensive care unit (ICU) length of stay, hospital length of stay, fluid culture results, and hospital mortality.

• Sepsis

• CNA Rapid Sepsis Dx

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. Patient 18 years of age or older at the time of enrollment

2. Presence of any of the following high-risk features:

   • Victims of trauma with either an Injury Severity Score of ≥ 15 or a Glasgow Coma Score of ≤ 8[2] OR
   • Any patient undergoing high-risk surgical procedures including any emergency surgery and high risk elective surgery procedures involving the thorax, esophagus, stomach, small bowel, large bowel [3, 4] OR
   • Any patient being admitted to any ICU setting for any reason with no current evidence or suspicion of active infection (by primary team).[5, 6]

3. Able to collect sample within 24 hours of presentation to the hospital.

Exclusion Criteria:

1. Prisoners or in police custody
2. Pregnancy
3. Pre-existing infection for which patient is being treated with antibiotics as an outpatient.
4. Plan for ongoing antibiotic therapy by treating team (up to three doses antibiotics for peri-procedure prophylaxis is allowable).
5. Moribund, unlikely to survive the duration of active enrollment
6. Comfort care measures in place or ordered at time of screening OR indication from treating team that active medical care will not be pursued due to patient's condition or patient's/family's wishes.
7. Palliative care or hospice consult at time of screening.

Observational Model

Cohort

Time Perspective

Prospective

Lead Sponsor

Robert EhrmanOTHER

tmazzocco@wayne.edu313-966-1829

rramdeo@northwell.edu516-465-5400